Literature DB >> 21548892

Use of a negative selectable marker for rapid selection of recombinant vaccinia virus.

Stacy D White1, Kip Conwell, Jeffrey O Langland, Bertram L Jacobs.   

Abstract

Vaccinia virus has been a powerful tool in molecular biology and vaccine development. The relative ease of inserting and expressing foreign genes combined with its broad host range has made it an attractive antigen delivery system against many heterologous diseases. Many different approaches have been developed to isolate recombinant vaccinia virus generated from homologous recombination; however, most are time-consuming, often requiring a series of passages or specific cell lines. Herein we introduce a rapid method for isolating recombinants using the antibiotic coumermycin and the interferon-associated PKR pathway to select for vaccinia virus recombinants. This method uses a negative selection marker in the form of a fusion protein, GyrB-PKR, consisting of the coumermycin dimerization domain of Escherichia coli gyrase subunit B fused to the catalytic domain of human PKR. Coumermycin-dependent dimerization of this protein results in activation of PKR and the phosphorylation of translation initiation factor, eIF2α. Phosphorylation of this factor leads to an inhibition of protein synthesis, and an inhibition of virus replication. In the presence of coumermycin, recombinants are isolated due to the loss of this coumermycin-sensitive gene by homologous recombination. We demonstrate that this method of selection is highly efficient and requires limited rounds of enrichment to isolate recombinant virus.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21548892      PMCID: PMC8240472          DOI: 10.2144/000113667

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  19 in total

1.  Engineering recombinant poxviruses using a compact GFP-blasticidin resistance fusion gene for selection.

Authors:  Yik Chun Wong; Leon C W Lin; Carolina R Melo-Silva; Stewart A Smith; David C Tscharke
Journal:  J Virol Methods       Date:  2010-11-10       Impact factor: 2.014

Review 2.  Translational control in mammalian cells.

Authors:  J W Hershey
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

3.  Characterization of viral double-stranded RNA-binding proteins.

Authors:  B L Jacobs; J O Langland; T Brandt
Journal:  Methods       Date:  1998-07       Impact factor: 3.608

Review 4.  PKR--a protein kinase regulated by double-stranded RNA.

Authors:  M J Clemens
Journal:  Int J Biochem Cell Biol       Date:  1997-07       Impact factor: 5.085

5.  A cellular screening assay to test the ability of PKR to induce cell death in mammalian cells.

Authors:  Inbar Friedrich; Menahem Eizenbach; Julia Sajman; Hannah Ben-Bassat; Alexander Levitzki
Journal:  Mol Ther       Date:  2005-08-08       Impact factor: 11.454

6.  The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs.

Authors:  J A Ali; A P Jackson; A J Howells; A Maxwell
Journal:  Biochemistry       Date:  1993-03-16       Impact factor: 3.162

7.  Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants.

Authors:  C A Franke; C M Rice; J H Strauss; D E Hruby
Journal:  Mol Cell Biol       Date:  1985-08       Impact factor: 4.272

8.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

9.  Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains of E3L.

Authors:  Jeffrey O Langland; Bertram L Jacobs
Journal:  Virology       Date:  2004-07-01       Impact factor: 3.616

10.  Dominant host range selection of vaccinia recombinants by rescue of an essential gene.

Authors:  G W Holzer; W Gritschenberger; J A Mayrhofer; V Wieser; F Dorner; F G Falkner
Journal:  Virology       Date:  1998-09-15       Impact factor: 3.616

View more
  7 in total

Review 1.  Reflections on the early development of poxvirus vectors.

Authors:  Bernard Moss
Journal:  Vaccine       Date:  2013-04-10       Impact factor: 3.641

2.  MAVERICC: Marker-free Vaccinia Virus Engineering of Recombinants through in vitro CRISPR/Cas9 Cleavage.

Authors:  Ethan Laudermilch; Kartik Chandran
Journal:  J Mol Biol       Date:  2021-02-24       Impact factor: 5.469

3.  Intranasal immunization with a vaccinia virus vaccine vector expressing pre-fusion stabilized SARS-CoV-2 spike fully protected mice against lethal challenge with the heavily mutated mouse-adapted SARS2-N501Y MA30 strain of SARS-CoV-2.

Authors:  Karen V Kibler; Mateusz Szczerba; Douglas Lake; Alexa J Roeder; Masmudur Rahman; Brenda G Hogue; Lok-Yin Roy Wong; Stanley Perlman; Yize Li; Bertram L Jacobs
Journal:  bioRxiv       Date:  2021-12-08

4.  Intranasal Immunization with a Vaccinia Virus Vaccine Vector Expressing Pre-Fusion Stabilized SARS-CoV-2 Spike Fully Protected Mice against Lethal Challenge with the Heavily Mutated Mouse-Adapted SARS2-N501YMA30 Strain of SARS-CoV-2.

Authors:  Karen V Kibler; Mateusz Szczerba; Douglas Lake; Alexa J Roeder; Masmudur Rahman; Brenda G Hogue; Lok-Yin Roy Wong; Stanley Perlman; Yize Li; Bertram L Jacobs
Journal:  Vaccines (Basel)       Date:  2022-07-23

5.  Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques.

Authors:  Gerard Zurawski; Sandra Zurawski; Anne-Laure Flamar; Laura Richert; Ralf Wagner; Georgia D Tomaras; David C Montefiori; Mario Roederer; Guido Ferrari; Christine Lacabaratz; Henri Bonnabau; Peter Klucar; Zhiqing Wang; Kathryn E Foulds; Shing-Fen Kao; Nicole L Yates; Celia LaBranche; Bertram L Jacobs; Karen Kibler; Benedikt Asbach; Alexander Kliche; Andres Salazar; Steve Reed; Steve Self; Raphael Gottardo; Lindsey Galmin; Deborah Weiss; Anthony Cristillo; Rodolphe Thiebaut; Giuseppe Pantaleo; Yves Levy
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

6.  Immunization of Pigs by DNA Prime and Recombinant Vaccinia Virus Boost To Identify and Rank African Swine Fever Virus Immunogenic and Protective Proteins.

Authors:  James K Jancovich; Dave Chapman; Debra T Hansen; Mark D Robida; Andrey Loskutov; Felicia Craciunescu; Alex Borovkov; Karen Kibler; Lynnette Goatley; Katherine King; Christopher L Netherton; Geraldine Taylor; Bertram Jacobs; Kathryn Sykes; Linda K Dixon
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

7.  Development and Validation of an ELISA for the Detection of Bluetongue Virus Serotype 4-Specific Antibodies.

Authors:  Emmanuel Bréard; Mathilde Turpaud; Georges Beaud; Lydie Postic; Aurore Fablet; Martin Beer; Corinne Sailleau; Grégory Caignard; Cyril Viarouge; Bernd Hoffmann; Damien Vitour; Stéphan Zientara
Journal:  Viruses       Date:  2021-08-31       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.